{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T01:22:42Z","timestamp":1770427362538,"version":"3.49.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3873,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.bbmt.2004.05.008","type":"journal-article","created":{"date-parts":[[2004,8,17]],"date-time":"2004-08-17T09:09:08Z","timestamp":1092733748000},"page":"579-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology"],"prefix":"10.1016","volume":"10","author":[{"given":"Andrew","family":"Grigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2004.05.008_BIB1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/10428199909167388","article-title":"Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin\u2019s lymphoma","volume":"32","author":"Bachier","year":"1999","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/blre.1999.0125","article-title":"Allogeneic bone marrow transplantation for lymphoma","volume":"14","author":"Bierman","year":"2000","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB3","first-page":"1","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies","volume":"82","author":"Sureda","year":"2003","journal-title":"Am J Hematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB5","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1083-8791(03)00128-9","article-title":"Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan","volume":"9","author":"Ritchie","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB7","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB8","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(05)60328-5","article-title":"Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)","volume":"352","author":"Mandigers","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.bmt.1701587","article-title":"Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin\u2019s lymphoma","volume":"23","author":"Bernard","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB10","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbmt.2004.05.008_BIB12","first-page":"76a","article-title":"Nonmyeloablative haematopoietic stem cell transplants (NMHSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies","volume":"100","author":"Maris","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.2000.18.3.702","article-title":"Allogeneic transplantation for low grade lymphoma","volume":"18","author":"Van Besien","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1703573","article-title":"Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma","volume":"29","author":"Forrest","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB16","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"10","author":"Van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB17","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","article-title":"Syngeneic haematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma","volume":"20","author":"Bierman","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB18","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1703255","article-title":"Stem cell transplantation for mantle cell lymphoma","volume":"28","author":"Sweetenham","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bmt.1701540","article-title":"Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma","volume":"23","author":"Grigg","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L","article-title":"Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma","volume":"65","author":"Sohn","year":"2000","journal-title":"Am J Hematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB23","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem cell transplantation for advanced\/recurrent mantle cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB24","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol."},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2004.05.008_BIB26","first-page":"78","article-title":"Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma","volume":"13","author":"Khouri","year":"2002","journal-title":"Ann Oncol."},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2004.05.008_BIB27","first-page":"8","article-title":"Mantle cell lymphoma\u2014update on results after R-HCVAD without stem cell transplant","volume":"13","author":"Romaguera","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB28","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft versus leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB30","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft versus leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogeneic stem-cell transplantation","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.leu.2402530","article-title":"Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia","volume":"16","author":"Dreger","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB32","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB33","first-page":"198a","article-title":"Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin\u2019s lymphoma","volume":"102","author":"Peggs","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.1999.17.4.1234","article-title":"Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies","volume":"17","author":"Porter","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB35","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/bbmt.2001.v7.pm11349810","article-title":"Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation","volume":"7","author":"Porter","year":"2001","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"10.1016\/j.bbmt.2004.05.008_BIB37","first-page":"144a","article-title":"Reduced intensity allogeneic stem cell transplantation for Hodgkin\u2019s disease","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbmt.2004.05.008_BIB38","first-page":"620a","article-title":"Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin\u2019s disease (HD)","volume":"100","author":"Anderlini","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1083-8791(03)70007-X","article-title":"BEAM allogeneic transplantation for patients with Hodgkin\u2019s disease who relapse after autologous transplantation is safe and effective","volume":"9","author":"Cooney","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB41","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","article-title":"Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma","volume":"19","author":"Akpek","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB42","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin\u2019s disease","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB43","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.1997.15.4.1595","article-title":"Role of a second transplant in the management of poor prognosis lymphomas","volume":"15","author":"Vandenberghe","year":"1997","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1703788","article-title":"Richter\u2019s syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion","volume":"31","author":"Espanol","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation","volume":"19","author":"Van Besien","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bmt.1701611","article-title":"Successful treatment of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation with donor lymphocyte infusion failed to prevent recurrence of primary disease","volume":"23","author":"Cesaro","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1083-8791(00)70056-5","article-title":"Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies","volume":"6","author":"Spitzer","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(97)89488-0","article-title":"Allogeneic bone marrow transplantation for poor-prognosis lymphoma","volume":"100","author":"Van Besien","year":"1996","journal-title":"Am J Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin\u2019s lymphoma (excluding Burkitt and lymphoblastic lymphoma)","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB51","first-page":"427a","article-title":"Nonmyeloablative conditioning followed by allogeneic transplantation has a better outcome than high-dose chemotherapy plus autografting in non-Hodgkin lymphomas with T-cell histology","volume":"100","author":"Corradini","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem-cell transplantation in patients with high risk aggressive non-Hodgkin\u2019s lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB53","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","article-title":"A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma","volume":"101","author":"Levine","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB54","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB55","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bmt.1700961","article-title":"Early cyclosporin taper in high risk sibling allogeneic bone marrow transplants","volume":"20","author":"Abraham","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB56","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10428190290017051","article-title":"Graft versus Burkitt\u2019s lymphoma effect after allogeneic marrow transplantation","volume":"43","author":"Grigg","year":"2002","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB57","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1703872","article-title":"Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen","volume":"31","author":"Soligo","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB59","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","article-title":"Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma","volume":"138","author":"Guitart","year":"2002","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1704136","article-title":"Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation","volume":"32","author":"Fijnheer","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB61","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.TP.0000072014.83469.2D","article-title":"Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen","volume":"76","author":"Mapara","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB62","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2002-01-0023","article-title":"Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras","volume":"100","author":"Mapara","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nm0602-575","article-title":"Acute graft-versus-host disease does not require alloantigen expression on host epithelium","volume":"8","author":"Teshima","year":"2002","journal-title":"Nat Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nri775","article-title":"Cytolytic pathways in haematopoietic stem-cell transplantation","volume":"2","author":"van den Brink","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB65","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.188.11.1977","article-title":"B cells directly tolerize CD8(+) T cells","volume":"188","author":"Bennett","year":"1998","journal-title":"J Exp Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB66","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.4049\/jimmunol.170.12.5897","article-title":"B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells","volume":"170","author":"Parekh","year":"2003","journal-title":"J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB67","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.4049\/jimmunol.163.8.4284","article-title":"Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation","volume":"163","author":"Skok","year":"1999","journal-title":"J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.176.2.381","article-title":"Expression of a transgenic T cell receptor beta chain enhances collagen-induced arthritis","volume":"176","author":"Mori","year":"1992","journal-title":"J Exp Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB70","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm0598-627","article-title":"B cells inhibit induction of T cell-dependent tumor immunity","volume":"4","author":"Qin","year":"1998","journal-title":"Nat Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB71","article-title":"Resting B cells impair antigen-specific tumour immunity via a MHC class-I independent mechanism","volume":"58","author":"Watt","year":"2003","journal-title":"Scand J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB72","first-page":"2836","article-title":"CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells","volume":"63","author":"Lapointe","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB73","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood.V100.1.200","article-title":"Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(\u2212) plasmacytoma cells","volume":"100","author":"Dotti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB74","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood.V90.5.1927","article-title":"CD40 ligand induces an antileukemia immune response in vivo","volume":"90","author":"Dilloo","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB75","unstructured":"Ritchie DS, Yang J, Hermans IF, Ronchese F. B Lymphocytes activated by CD40 ligand induce an antigen specific anti-tumor immune response by direct and indirect activation of CD8+ T cells. Scand J Immunol. In press."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB76","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/eji.1830240118","article-title":"Induction of B cell costimulatory function by recombinant murine CD40 ligand","volume":"24","author":"Kennedy","year":"1994","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB77","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2567.1998.00550.x","article-title":"Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin\u2019s lymphoma","volume":"94","author":"Van-Dreese","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0301-472X(98)00059-9","article-title":"Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin\u2019s lymphomas","volume":"27","author":"Chaperot","year":"1999","journal-title":"Exp Hematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB79","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V96.6.2219","article-title":"Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures","volume":"96","author":"Andersen","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nat Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB81","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB82","first-page":"1656","article-title":"Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines","volume":"9","author":"Gitelson","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB83","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.4049\/jimmunol.164.6.3095","article-title":"CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity","volume":"164","author":"Hermans","year":"2000","journal-title":"J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB84","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.171.9.4604","article-title":"CD4+ CD25+ T cells lyse antigen-presenting B cells by fas-fas ligand interaction in an epitope-specific manner","volume":"171","author":"Janssens","year":"2003","journal-title":"J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB85","first-page":"1275","article-title":"Suppression of MHC class I antigens in oncogenic transformants","volume":"24","author":"Seliger","year":"1996","journal-title":"Exp Hematol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB86","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"96","author":"Riemersma","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1101\/sqb.1999.64.71","article-title":"The lymphochip","volume":"64","author":"Alizadeh","year":"1999","journal-title":"Cold Spring Harb Symp Quant Biol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB89","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3562::AID-IMMU3562>3.0.CO;2-R","article-title":"Distinct migration patterns of naive and effector CD8 T cells in the spleen","volume":"29","author":"Potsch","year":"1999","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB90","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1073\/pnas.94.4.1366","article-title":"Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function","volume":"94","author":"Baker","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB91","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO;2-Y","article-title":"Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22","volume":"32","author":"Ghia","year":"2002","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI200316950","article-title":"Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720","volume":"111","author":"Kim","year":"2003","journal-title":"J Clin Invest."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB93","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/01.TP.0000083891.14089.B8","article-title":"FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model","volume":"76","author":"Lee","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB94","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1440-1711.2003.t01-1-01164.x","article-title":"Cytotoxic T cells with reciprocal antigenic peptide presentation function are not generally resistant to mutual lysis","volume":"81","author":"Staege","year":"2003","journal-title":"Immunol Cell Biol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mjd.2002.122188","article-title":"Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Masood","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB96","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood-2002-02-0419","article-title":"Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants","volume":"100","author":"Billiau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/bbmt.1999.v5.pm10392958","article-title":"Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets","volume":"5","author":"Johnson","year":"1999","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB98","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1083-8791(03)00077-6","article-title":"Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor responses in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation","volume":"9","author":"Dey","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB99","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1074-7613(03)00055-4","article-title":"Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse","volume":"18","author":"Sato","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB101","first-page":"5797","article-title":"Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease","volume":"60","author":"Anderson","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB102","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1702785","article-title":"Transfer of idiotypic protein primed allogeneic marrow graft elicits potent graft-versus-myeloma effects in mice","volume":"27","author":"Zeis","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB103","first-page":"796","article-title":"Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation","volume":"62","author":"Teshima","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbmt.2004.05.008_BIB104","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V95.7.2426","article-title":"Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease","volume":"95","author":"Anderson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2004.05.008_BIB105","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.4049\/jimmunol.171.12.6941","article-title":"Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host","volume":"171","author":"Zoller","year":"2003","journal-title":"J Immunol."}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879104002526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879104002526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:20:46Z","timestamp":1761056446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879104002526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":105,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S1083879104002526"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2004.05.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2004.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}